UBS AM’s Black Diamond Therapeutics BDTX Stock Holding History

UBS AM’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$509	Hold	275	–	–	﹤0.01%	3655
2026 Q1	$586	Buy	+275	New	+$654	﹤0.01%	3720
2025 Q3	–	Sell	-100,000	Closed	-$248K	–	2315
2025 Q2	$248K	Buy	+100,000	New	+$193K	﹤0.01%	2543
2024 Q4	–	Sell	-18,600	Closed	-$80.9K	–	2663
2024 Q3	$80.9K	Hold	18,600	–	–	﹤0.01%	2785
2024 Q2	$86.7K	Buy	+18,600	New	+$99.8K	﹤0.01%	2775
2021 Q4	–	Sell	-24,100	Closed	-$204K	–	2847
2021 Q3	$204K	Hold	24,100	–	–	﹤0.01%	2689
2021 Q2	$294K	Buy	24,100 +13,600	+130%	+$269K	﹤0.01%	2649
2021 Q1	$255K	Buy	10,500 +3,000	+40%	+$80.9K	﹤0.01%	2520
2020 Q4	$240K	Buy	+7,500	New	+$246K	﹤0.01%	2464

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

UBS AM's BDTX Position: Q2 2026 in Review

UBS AM held its Black Diamond Therapeutics (BDTX) position steady in Q2 2026 at 275 shares worth $509. The position accounts for ﹤0.01% of the portfolio, ranked #3655.

UBS AM first reported a position in BDTX in Q4 2020 and has held it in 9 quarters since. The position peaked at $294K in Q2 2021. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

UBS AM held 275 shares of Black Diamond Therapeutics worth $509 as of Q2 2026.
UBS AM left its Black Diamond Therapeutics share count unchanged in Q2 2026.
Black Diamond Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3655 holding.
UBS AM first reported a position in Black Diamond Therapeutics in Q4 2020 and has held it in 9 quarters since.
UBS AM's Black Diamond Therapeutics position peaked at $294K in Q2 2021.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.